Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Med Chem ; 42(5): 805-18, 1999 Mar 11.
Artigo em Inglês | MEDLINE | ID: mdl-10072679

RESUMO

Screening of our chemical library using a rat corticotropin-releasing hormone (CRH) receptor assay led to the discovery that 2-anilinopyrimidine 15-1 weakly displaced [125I]-0-Tyr-oCRH from rat frontal cortex homogenates when compared to the known peptide antagonist alpha-helical CRH(9-41) (Ki = 5700 nM vs 1 nM). Furthermore, 15-1 weakly inhibited CRH-stimulated adenylate cyclase activity in the same tissue, but it was less potent than alpha-helical CRH(9-41) (IC50 = 20 000 nM vs 250 nM). Systematic structure-activity relationship studies, using the cloned human CRH1 receptor assay, defined the pharmacophore for optimal binding to hCRH1 receptors. Several high-affinity 2-anilinopyrimidines and -triazines were discovered, some of which had superior pharmacokinetic profiles in the rat. This paper describes the structure-activity studies which improved hCRH1 receptor binding affinity and pharmacokinetic parameters in the rat. Compound 28-17 (mean hCRH1 Ki = 32 nM) had a significantly improved pharmacokinetic profile in the rat (19% oral bioavailability at 30 mg/kg) as well as in the dog (20% oral bioavailability at 5 mg/kg) relative to the early lead structures.


Assuntos
Pirimidinas/síntese química , Receptores de Hormônio Liberador da Corticotropina/antagonistas & inibidores , Triazinas/síntese química , Animais , Disponibilidade Biológica , Cães , Lobo Frontal/metabolismo , Humanos , Técnicas In Vitro , Pirimidinas/química , Pirimidinas/farmacocinética , Pirimidinas/farmacologia , Ratos , Receptores de Hormônio Liberador da Corticotropina/metabolismo , Proteínas Recombinantes/metabolismo , Relação Estrutura-Atividade , Triazinas/química , Triazinas/farmacocinética , Triazinas/farmacologia
2.
J Med Chem ; 42(5): 819-32, 1999 Mar 11.
Artigo em Inglês | MEDLINE | ID: mdl-10072680

RESUMO

As described in the preceding paper (Arvanitis et al. J. Med. Chem. 1999, 42), anilinopyrimidines I were identified as potent antagonists of corticotropin-releasing hormone-1 receptor (CRH1-R, also referred to as corticotropin-releasing factor, CRF1-R). Our next goal was to understand the receptor-bound conformation of the antagonists and to use this information to help guide preclinical optimization of the series and to develop new leads. Since receptor structural information was not available, we assumed that these small, high-affinity antagonists would tend to bind in conformations at or energetically close to their global minima and that rigid analogues that maintained the important stereoelectronic features of the bound anilinopyrimidine would also bind tightly. Conformational preferences and barriers to rotation of the anilinopyrimidines were determined by semiempirical methods, and X-ray and variable-temperature NMR spectroscopy provided experimental results that correlated well with calculated structures. Using these data, a key dihedral angle was constrained to design fused-ring analogues, substituted N-arylpyrrolopyridines II, synthesis of which provided CRH1 receptor antagonists with potency equal to that of the initial congeneric leads (Ki = 1 nM) and which closely matched the conformation held by the original compound, as determined by crystallography. In addition to providing a useful template for further analogue synthesis, the study unequivocally determined the active conformation of the anilinopyrimidines. Theoretical and spectroscopic studies, synthesis, and receptor binding data are presented.


Assuntos
Piridinas/síntese química , Pirimidinas/síntese química , Receptores de Hormônio Liberador da Corticotropina/antagonistas & inibidores , Cristalografia por Raios X , Desenho de Fármacos , Ligantes , Espectroscopia de Ressonância Magnética , Modelos Moleculares , Conformação Molecular , Piridinas/química , Pirimidinas/química , Soluções , Relação Estrutura-Atividade
3.
Br J Clin Psychol ; 35(4): 617-26, 1996 11.
Artigo em Inglês | MEDLINE | ID: mdl-8955547

RESUMO

Bentall & Thompson (1990) selected participants on the basis of high, medium and low scores on the Hypomanic Personality Scale. In an emotional Stroop test, the high hypomanic participants showed interference of colour naming for depression-related but not euphoria-related words. The current study tests the hypothesis that the effects found were mediated by anxiety, and not hypomania as claimed. Bentall & Thompson's study was repeated but measures of state of trait anxiety were also taken. When analysis was restricted to three subgroups selected in the same manner as in Bentall & Thompson's (1990) study, the findings were very similar to those found in that study and the hypomania-related interference effects were found to occur even when anxiety levels were taken into account. Further analyses of data from the full sample of participants supported the idea that hypomanic personality might reflect a partially successful means of coping with depressive tendencies.


Assuntos
Sintomas Afetivos/psicologia , Ansiedade/psicologia , Emoções , Euforia , Adulto , Análise de Variância , Cor , Mecanismos de Defesa , Depressão/psicologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Teoria Psicanalítica , Testes Psicológicos , Tempo de Reação , Autoimagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...